• INmune Bio received MHRA written alignment supporting a planned 2026 UK conditional marketing authorization filing for CORDStrom-derived Ebstrocel in RDEB.
• Clinical results were already presented from the MissionEB Phase 2 study, with regulators citing meaningful symptom relief, notably pain and itch.
• MHRA also highlighted limits in durability of wound-related effects after treatment ended, shaping positioning toward supportive therapy use.
• Feedback supports a confirmatory Phase 3 trial expected to open in 2026, with endpoints refocused toward patient-relevant symptom benefits.
• Management expects EU and US submissions to follow in late 2026 or early 2027, subject to alignment and required filings.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. INmune Bio Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-26-071082), on June 23, 2026, and is solely responsible for the information contained therein.